All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F17%3A00102137" target="_blank" >RIV/00216224:14110/17:00102137 - isvavai.cz</a>

  • Result on the web

    <a href="http://dx.doi.org/10.1080/08880018.2017.1373314" target="_blank" >http://dx.doi.org/10.1080/08880018.2017.1373314</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1080/08880018.2017.1373314" target="_blank" >10.1080/08880018.2017.1373314</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma

  • Original language description

    The metronomic therapy concept uses low doses of continuously applied chemotherapeutic, anti-angiogenetic, and immunomodulating drugs. Twenty patients with recurrent and 3 with refractory high-risk neuroblastoma were treated by the metronomic concept using celecoxib, cyclophosphamide, vinblastine, and etoposide for up to 24 months. The outcome was compared to 274 matched patients with a first recurrence from stage 4 neuroblastoma using the variables time from diagnosis to first recurrence, number of organs involved, and MYCN amplification. All were treated with dose-intensive conventional chemotherapy. The study patients experienced 1-3 recurrences and had 1-3 sites involved (osteomedullary, primary tumor, central nervous system, lymph nodes, liver, lungs) before the metronomic therapy started. Two patients in complete remission and three with active refractory disease following recurrence treatment were excluded from the outcome analysis. The curves for secondary event-free and overall survival demonstrated no significant differences.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30204 - Oncology

Result continuities

  • Project

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2017

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Pediatric Hematology and Oncology

  • ISSN

    0888-0018

  • e-ISSN

    1521-0669

  • Volume of the periodical

    34

  • Issue of the periodical within the volume

    5

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    12

  • Pages from-to

    308-319

  • UT code for WoS article

    000419983600006

  • EID of the result in the Scopus database

    2-s2.0-85034232887